Welcome to our dedicated page for Teleflex news (Ticker: TFX), a resource for investors and traders seeking the latest updates and insights on Teleflex stock.
Teleflex Incorporated (NYSE: TFX) is a global medical technology company whose news flow reflects its activity across anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. Company announcements frequently highlight portfolio developments, clinical research, financial performance, and governance changes, giving investors and healthcare professionals insight into how the business is evolving.
Recent Teleflex news has included leadership transitions, with the Board appointing a long-serving director as Interim President and Chief Executive Officer and naming a new Chair of the Board, as well as updates on the search for a permanent CEO. The company has also reported on strategic portfolio actions, such as agreements to sell its Original Equipment Manufacturing and Development Services business and its acute care and interventional urology segments, reflecting a shift toward a more focused organization centered on core critical care and high-acuity hospital markets.
On the operational side, Teleflex regularly issues quarterly earnings releases and outlook updates, detailing revenue by region and global product category, along with commentary on non-GAAP measures like adjusted revenue and adjusted constant currency revenue growth. Dividend declarations and share repurchase authorizations are also communicated through press releases and associated SEC filings.
For those following clinical and product developments, Teleflex news covers topics such as the launch of the Barrigel™ rectal spacer in new markets and support for investigator-initiated trials like the DUBSTENT DIABETES study in interventional cardiology. Visitors to this TFX news page can review these updates in one place to understand how Teleflex’s strategy, portfolio, and financial profile are changing over time.
Teleflex, ticker TFX, has presented data on the UroLift System for treating benign prostatic hyperplasia (BPH) at the EAU 2020 virtual congress. The studies confirmed the system's safety and effectiveness in diverse patient groups, highlighting significant improvements in the International Prostate Symptom Score (IPSS) over various time points. Key findings include 60% of patients being catheter-free by one month post-treatment and 83% recommending the procedure. The UroLift System is indicated for men with enlarged prostates and aims to provide rapid symptom relief without the adverse effects commonly associated with other treatments.
Teleflex Incorporated (NYSE: TFX) will release its second quarter 2020 financial results on July 30, 2020, before market open. An investor conference call is scheduled for the same day at 8:00 a.m. (ET), accessible via a live audio webcast on their website. A replay of the call will be available from 11:00 a.m. (ET) on July 30 to 11:00 a.m. (ET) on August 4, 2020. Teleflex specializes in medical technologies aimed at improving health and quality of life, with a diverse portfolio across various medical fields.
Teleflex announced survey results revealing that a significant number of American men over 40 are prescribed multiple medications, particularly for benign prostatic hyperplasia (BPH). The surveys showed that many believe BPH is solely medication-treatable, despite alternatives like the UroLift System being available. Over 54% of men with BPH use medication, with 27% having stopped due to side effects. The need for better patient education on minimally invasive treatments is emphasized, with over 175,000 men having opted for the UroLift System, a treatment that avoids common medication side effects.
Teleflex Incorporated (NYSE: TFX) has introduced an online submission portal for its COVID-19 Humanitarian Product Donation Program. The initiative aims to supply critical medical devices, including Personal Protective Equipment, to healthcare providers and patients battling COVID-19. Teleflex emphasizes that the program is strictly humanitarian, with no expectation of commercial gain. Donations will be reported to relevant governmental agencies to ensure transparency. For further details, interested parties can reach out via the provided email or visit the Teleflex website.
Teleflex (NYSE: TFX) has released data showing the superior efficacy of the UroLift® System for treating benign prostatic hyperplasia (BPH) compared to the Rezum™ steam injection. The study revealed that 93% of patients treated with UroLift were catheter-free by day three, compared to just 45% for Rezum. Additionally, 83% of UroLift patients expressed satisfaction with their treatment, versus 65% for Rezum. The UroLift System allows for rapid recovery and preservation of sexual function, highlighting its growing acceptance in urological care.
WAYNE, Pa., June 03, 2020 - Thomas Powell, CFO of Teleflex (NYSE: TFX), will present at the Raymond James 2020 Human Health Innovation Conference on June 17, 2020 at 2:20 p.m. ET. A live audio webcast of his presentation, along with slides, will be available on the Teleflex investor website.
Teleflex is a global medical technology provider focused on innovative solutions across various healthcare fields including vascular access, anesthesia, and emergency medicine.
Teleflex Incorporated (NYSE: TFX) has announced the enrollment of the first patient in a pivotal clinical study evaluating the effectiveness of its coronary guidewires and specialty catheters in Chronic Total Occlusion (CTO) procedures. The CTO-PCI study aims to enroll up to 150 patients at roughly 15 sites across the US. The study will assess key metrics, including successful guidewire placement and major adverse cardiac events. The principal investigators from notable institutions emphasize the importance of this research in enhancing techniques for treating complex coronary blockages.
Teleflex announced the pricing of a private offering of $500 million in 4.25% senior notes due 2028, scheduled to close on May 27, 2020. The notes will be guaranteed by its wholly-owned domestic subsidiaries. Proceeds will be used to repay borrowings under its revolving credit facility. This offering is made under exemptions from the Securities Act of 1933, targeting qualified institutional buyers and certain non-U.S. persons. The notes have not been registered and cannot be sold in the U.S. without registration or exemption.
Teleflex has announced a private offering of $500 million in senior notes due 2028, subject to market conditions. These notes will be guaranteed by its wholly-owned subsidiaries. The proceeds will be used to repay borrowings from its revolving credit facility. This offering is targeted at qualified institutional buyers and non-U.S. persons outside the U.S. and will not be registered under the Securities Act.
On May 18, 2020, Teleflex presented data at the AUA 2020 Virtual Experience highlighting the UroLift® System’s benefits for treating benign prostatic hyperplasia (BPH). Studies demonstrated that the minimally invasive treatment significantly preserves sexual function compared to traditional medical therapies. In a meta-analysis involving 1,039 men, UroLift patients reported substantial improvements in ejaculatory and erectile function over 48 months. Additionally, a real-world study found equivalent safety profiles across patient groups, with 84% of urinary retention patients becoming catheter-independent post-treatment.
FAQ
What is the current stock price of Teleflex (TFX)?
What is the market cap of Teleflex (TFX)?
